In June 2022, the FTC launched a market study of PBMs and the impact of their practices on pharmacies, payers, doctors, and patients. In our conversation, we learned that, historically, PBMs were extremely successful in encouraging the adoption of generic drugs, saving health plans and patients considerable cost. Listen to the episode if you want to learn more about what goes into the price that you pay for your prescription. The companies have responded, in part, by listing at least 10 drugs at a lower price. And many health plans are choosing the more-expensive version, according to data analysis conducted for The Wall Street Journal.

Source: Wall Street Journal November 15, 2023 08:29 UTC